

00 Rec'd PCT/PTO 18 MAY 1999

FORM PTO-1390
(REV 5-93)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.
P564-9010

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

DATE: May 18, 1999

U.S. APPLN. NO.
(IF KNOWN, SEE 37 CFR 1.5)

09/297092

INTERNATIONAL APPLICATION NO.
PCT/EP97/06463


INTERNATIONAL FILING DATE
19 November 1997

PRIORITY DATE CLAIMED
19 November 1996

TITLE OF INVENTION: COMPOUNDS WITH IMPROVED CARTILAGE-INDUCING AND/OR BONE-INDUCING ACTIVITY

APPLICANT(S) FOR DO/EO/US: Michael PAULISTA, Jens POHL, Joachim PABST, Helmut HEIDE

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
(THE BASIC FILING FEE IS ATTACHED)
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).
 4. ☒ A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
 6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:
11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☒ Two assignment documents for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
 14. ☐ A substitute specification.
 15. ☐ A change of power of attorney and/or address letter.
 16. ☒ Other items or information: Small Entity Statements (2) PCT/IPEA/416, PCT/IPEA/409, PCT/RO/101
 CHECK NO. 196150
 Drawing - 1 sheet

U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.50)		INTERNATIONAL APPLICATION NO. PCT/EP97/06463		ATTORNEY DOCKET NO. P564-9010 DATE: May 18, 1999	
17. <u>XX</u> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(6)): Search Report has been prepared by the EPO or JPO.....\$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00 Neither international preliminary examination fee (37 CFR 1.482) or international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.462) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$96.00				CALCULATIONS PTO USE ONLY <hr/>	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$840	
Surcharge of \$130.00 for furnishing the oath or declaration later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	13 - 20 =	00	X \$ 18.00	\$00	
Independent Claims	01 - 3 =	00	X \$ 78.00	\$00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$00	
TOTAL OF ABOVE CALCULATIONS =				\$840	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$420	
SUBTOTAL =				\$420	
Processing fee of \$130.00 for furnishing the English translation later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$00	
TOTAL NATIONAL FEE =				\$420	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$80	
TOTAL FEES ENCLOSED =				\$500	
				Amount to be refunded	\$
				Charged	\$
a. <u>XX</u> A check in the amount of \$ <u>500</u> to cover the above fees is enclosed. b. Please charge my Deposit Account No. <u>14-1060</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <u>XX</u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1060</u> .					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
NIKAI DO, MARMELESTEIN, MURRAY AND ORAM LLP Metropolitan Square 655 15th Street, N.W. Suite 330 - G Street Lobby Washington, D.C. 20005-5701 Telephone No. (202) 638-5000					
				 Robert B. Murray Reg. No. 22,980	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Michael PAULISTA et al

Serial No.: Unknown

Filed: May 18, 1999

For: COMPOUNDS WITH IMPROVED CARTILAGE-INDUCING AND/OR BONE-INDUCING ACTIVITY

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

May 18, 1999

Sir:

Prior to calculation of the filing fee and prior to the examination of this application, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 26, line 6, delete "3" and insert therefor --2--.

IN THE CLAIMS:

Please amend the claims as follows:

Claim 3, line 1, delete "or 2".

Claim 4, lines 1 or 2, delete "one of the claims 1 to 3" and insert therefor --claim 1--.

Claim 6, line 1, delete "claims 4 or 5" and insert therefor --claim 4--.

Claim 7, line 1, delete "claims 4, 5 or 6" and insert therefor --claim 4--.

Claim 8, line 2, delete "one of the claims 1 to 7" and insert therefor --claim 1--.

Claim 11, line 2, delete "one of the claims 1 to 7" and insert therefor --claim 1--.

Claim 12, lines 1 and 2, delete "one of the claims 1 to 7 or of a pharmaceutical composition as claimed in claim 11" and insert therefor --claim 1--.


Claim 13, lines 1 and 2, delete "one of the claims 1 to 7 or of a pharmaceutical composition as claimed in claim 11" and insert therefor --claim 1--.

REMARKS

The above amendment to the claims has been made to correct the multiple dependency of the claims and to put the application in better condition for examination.

In the event that any fees are due in connection with this paper, please charge our Deposit Account No. 14-1060.

Respectfully submitted,
NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP



Robert B. Murray
Attorney for Applicants
Reg. No. 22,980

Atty. Docket No.: P564-9010

Metropolitan Square
655 15th Street, N. W.
Suite 330 - G Street Lobby
Washington, D. C. 20005-5701
Tel (202) 638-5000
Fax (202) 638-4810

RBM/cb

Serial or Patent No.: _____ Docket No.: _____

Filed or Issued: _____

To: _____

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN)

I hereby declare that I am

- () the owner of the small business concern identified below:
(X) an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN GerontoCare GmbH Biomaterials & Medical Devices

ADDRESS OF CONCERN Rossberggring 107, D-64354 Reinheim/Odw., Germany

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduce 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, on concern controls or has the power to control the other, or a third party or parties control or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled Compounds with improved cartilage-inducing and/or bone-inducing activity by Inventor(s) Michael Paulista, Jens Pohl, Joachim Pabst, Helmut Heide described in

- () the specification filed herewith
() application serial no. _____ filed _____
() patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or 1.9(e), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____
() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING X Dr. Joachim Pabst

TITLE OF PERSON OTHER THAN OWNER X Marketing & Sales Manager Germany

ADDRESS OF PERSON SIGNING X Rossberggring 107, D-64354 Reinheim,

SIGNATURE X Joachim Pabst DATE X 13.05.1999

Serial or Patent No.: _____ Docket No.: _____

Filed or Issued: _____

To: _____

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN

I hereby declare that I am

- () the owner of the small business concern identified below:
(X) an official of the small business concern empowered to act on behalf
of the concern identified below:

NAME OF CONCERN Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH

ADDRESS OF CONCERN Czernyring 22, D-69115 Heidelberg, Germany

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled Compounds with improved cartilage-inducing and/or bone-inducing activity by Inventor(s) Michael Paulista, Jens Pohl, Joachim Pabst, Helmut Heide described in

- (X) the specification filed herewith
() application serial no. _____ filed _____
() patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____

ADDRESS _____

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Michael Paulista

TITLE OF PERSON OTHER THAN OWNER _____

ADDRESS OF PERSON SIGNING Biopharm mbH, Czernyring 22, 69115 HEIDELBERG

SIGNATURE M. Paulista

DATE J. 3. 98

510 Rec'd PCT/PTO 18 MAY 1999,

- 1 -

Compounds with improved cartilage-inducing and/or bone-inducing activity**Description**

The present invention concerns new improved compounds with cartilage-inducing and/or bone-inducing activity composed of one or several members of the TGF- β family, preferably MP52, or a DNA sequence coding therefor and a special carrier matrix composed of crystallographically phase-pure tricalcium phosphate. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones and to treat damage to cartilage and/or bone tissue.

Many growth factors from the TGF- β superfamily are relevant for a wide range of medical treatment methods and applications which in particular concern wound healing and tissue reconstruction. For a review of members of the TGF- β superfamily cf. e.g.: Roberts, A.B. & Sporn, M.B. Handbook of Experimental Pharmacology 95 (1990) 419-472; Kingsley, D.M., Genes & Development 8 (1994) 133-146 and the literature cited therein. The members include the TGF- β proteins such as TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4 and TGF- β 5, cf. e.g.: U.S. Patent 5,284,763; EP 0376785; U.S. Patent 4,886,747; Madisen, L. et al., DNA 7 (1988) 1-8; Derynck, R. et al., EMBO J. 7 (1988) 3737-3743; Jakowlew, S.B. et al., Mol. Endo. 2 (1988) 1186-1195; Kondaiah, P. et al., J. Biol. Chem. 265 (1990) 1089-1093. The activins/inhibins which have the previously known activin chains β A, β B, β C and β D form a further subfamily cf. e.g. Mason, A.J. et al., Biochem. Biophys. Res. Commun. 135 (1986) 957-964;

Hötten, G. et al., *Biochem. Biophys. Res. Commun.* 206 (1995) 608-613; Oda, S. et al., *Biochem. Biophys. Res. Commun.* 210 (1995) 581-588. GDF-12 can also be classed with this subfamily due to its amino acid homology (cf. WO 96/02559). It is known that βA and βB can also form a heterodimer $\beta A\beta B$ in addition to the homodimer. Combination with an α subunit forms the inhibins which essentially have the opposite activities compared to activins, cf: Vale, W. et al., *Handbook of Experimental Pharmacology* 95 (1990) 211-248; Vale, W. et al., *The Physiology of Reproduction*, Raven Press, New York (1994) 1861-1878. The members of the BMP (bone morphogenetic protein) family form a further subfamily which include the proteins BMP-2 (BMP-2a), BMP-3, BMP-3b, BMP-4 (BMP-2b), BMP-5, BMP-6, BMP-7 (OP-1), BMP-8 (OP-2), BMP-9, BMP-10, BMP-11, BMP-12 and BMP-13 cf. e.g.: Wozney, J.M. et al. *Science* 242 (1988) 1528-1534; Celeste, A.J. et al., *Proc. Natl. Acad. Sci. USA* 87 (1990) 9843-9847; Özkaynak, E. et al., *J. Biol. Chem.* 267 (1992) 25220-25227; Takao et al. *Biochem. Biophys. Res. Com.* 219 (1996) 656-662; WO 93/00432; WO 94/26893; WO 94/26892, WO 95/16035. A further subgroup is the GDF (growth differentiation factor) family which include GDF-1, GDF-3, GDF-9, GDF-10, GDF-11 as well as GDF-5, GDF-6 and GDF-7 which are particularly interesting for cartilage-induction and/or bone-induction c.f. McPherron, A.C. & Lee, S.-J., *J. Biol. Chem.* 268 (1993) 3444-3449; Storm, E.E. et al., *Nature* 368 (1994) 639-643; Lee, S.-J.; *Proc. Natl. Acad. Sci. USA* 88 (1991) 4250-4254; Cunningham et al. *Growth Factors* 12 (1995), 99-109; Hötten, G. et al., *Growth Factors* 13 (1996) 65-74; Chang, S.C. et al., *J. Biol. Chem.* 269 (1994) 28227-28234. There are some overlaps between the subgroups of the GDF and BMP family due to amino acid homologies. It was also possible to detect a cartilage-inducing

potential and bone-inducing potential for the TGF- β superfamily members dpp and 60A from *Drosophila* cf.: Sampath, T.K. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6004-6008. The proteins dorsalin and the bone formation-inducing protein are also of interest cf.: Basler, K. et al., Cell 73 (1993) 687-702; WO 94/01557. Heterodimers of various members have also been described cf.: Aono, A. et al., Biochem. Biophys. Res. Commun. 210 (1995) 670-677; WO 93/09229; EP 0 626 451. It is known that many members especially from the subfamilies of the TGF- β , BMP and GDF families have a cartilage-inducing and/or bone-inducing potential and members of the activin family can also influence bone formation at least in combination with other TGF- β superfamily members cf. for example Hock, J.M. et al., Endocrinol. 126 (1990) 421-426; Wang et al., Proc. Natl. Acad. Sci. USA 87 (1990) 2220-2224; Wozney et al., Mol. Reprod. Dev. 32 (1992) 160-167; Sampath et al., J. Biol. Chem. 267 (1992) 20352-20362; Ogawa, Y. et al., J. Biol. Chem. 267 (1992) 14233-14237; WO 88/00205; US-PS 5,013,649; WO 89/10409; WO 90/11366; WO 91/05802; WO 92/15323; WO 91/18098; WO 93/00432; WO 93/09229; WO 94/01557; WO 94/26893; WO 94/26892; WO 94/15949; WO 95/01801; WO 95/01802 and EP 0 626 451. Since some of the individual proteins act at different sites during the course of cartilage and bone induction, it can be assumed that a combination of various such proteins would be advantageous for the efficiency of cartilage and bone induction. Such protein mixtures are also encompassed by this invention.

The DNA and protein sequences of proteins of the TGF- β family i.e. MP52 and MP121 are described in WO 93/16099, WO 95/04819 and WO 96/01316. MP121 is the activin β C which has already been mentioned above. MP52 (sometimes

also named GDF5 in publications) for which a cartilage-inducing and bone-inducing potential has already been proven is of particular interest (WO 95/04819 and Hötten et al. Growth Factors 13 (1996) 65-74).

The members of the TGF- β superfamily which have a cartilage-inducing and/or bone-inducing potential are characterized in the mature part by high amino acid homologies and have the seven conserved cysteines which are typical for members of the TGF- β superfamily. The active form of members of this superfamily is usually always a homodimeric and/or heterodimeric protein. The cartilage-inducing and/or bone-inducing potential of these proteins is usually tested on inert carrier matrices which themselves have no cartilage-inducing and/or bone-inducing effect at all.

Already in the sixties intensive research work began on the applications of calcium phosphate ceramics as an implantable bone substitute (Bhaskar et al., Oral Surg. 32 (1971) 47) which was based on the chemical similarity of this group of compounds to the mineral component of bone. One of the first systematic investigations on the connections between the chemical and material parameters and the biological properties was carried out at the beginning of the seventies at the Battelle Institute (Heide, Köster et al., Z. Orthop. 118 (1979) 398 and Biotechn. Umschau 2 (1978) 226). In these investigations calcium phosphates with various $\text{CaO/P}_2\text{O}_5$ ratios were produced by sintering processes as granular and pelleted ceramic implant materials and tested in animal experiments. The major results of these studies can be summarized as follows:

(a) Calcium phosphate ceramics of particular compositions are characterized by an excellent bone tissue tolerance.

(b) The optimum tissue tolerance is mainly achieved with ceramics with a $\text{CaO/P}_2\text{O}_5$ ratio of 3/1 i.e. with tricalcium phosphate TCP, $\text{Ca}_3(\text{PO}_4)_2$ (or written $3\text{CaO}\cdot\text{P}_2\text{O}_5$ as a ceramic formula) and hydroxylapatite (HA) itself i.e. $[\text{Ca}_5(\text{PO}_4)_3\text{OH}]$ which can also be prepared synthetically. This result is logical since it is also known that the composition of the mineral bone component with its most important mineral component hydroxylapatite approximately corresponds to this ratio. Although TCP and HA have a similar chemical composition there are considerable differences in their solubility properties and other physical properties such as density and strength. The potential areas of application also of course depend on this.

(c) The two optimal biocompatible modifications of tricalcium phosphate TCP (i.e. the metastable high temperature modification α -TCP and especially the stable low temperature modification β -TCP) and hydroxylapatite HA are more or less biodegradable i.e. in biological storage they are degraded or absorbed more or less rapidly. α -TCP and β -TCP have a pronounced biodegradability according to Ramselaar et al., J. Materials Sci. 2 (1991) 63. The resorption of HA is very much less in a biological environment. TCP in a bone store tends to be degraded chemically according to experiments with radioactively labelled implant materials by Schuster, Heide et al., (unpublished report of the Battelle Institute Frankfurt) i.e. the dissolution

and metabolism of the dissolved products occurs without involvement of bone-degrading cells whereas the very much slower resorption of hydroxylapatite is based more on a specific action of bone-degrading cells (osteoclasts).

(d) The biocompatible calcium phosphate ceramics based on TCP and HA are integrated in the bone store largely without encapsulation by connective tissue as was impressively demonstrated in animal experiments in the seventies by the said Battelle working group among others. At that time the term "bioactivity" was introduced for this outstanding property.

During further development of the promising calcium phosphate ceramics it turned out that detailed knowledge of the complex crystal-chemical relationships of the system $\text{CaO-P}_2\text{O}_5$ ($+\text{H}_2\text{O}$) is an absolute prerequisite for a systematic optimization. Unfortunately in the past and still today many users ignore these requirements especially when materials based on the poorly biodegradable HA are used for typical temporary applications such as e.g. the sanitation of periodontal pockets. Important papers on this subject have been published by De Groot et al., *Biomaterials* 1 (1980) 47, and Bauer and Hohenberger, "Berichte der DKG" 66 (1989) 23.

Numerous implant materials that are nowadays still commonly available on the market which are composed of undefined mixtures of TCP and HA and other calcium phosphate phases such as dicalcium or tetracalcium phosphates and calcium phosphate glasses have adverse

biomedical properties such as provocation of connective tissue infiltration and activation of macrophages which may be accompanied by inflammatory reactions. The connective tissue encapsulation of materials with such a defective composition is then a manifestation of the rejection of the implant (Bauer and Hohenberger, "Berichte der DKG" 66 (1989) 23). The stoichiometric composition alone is not a criterium for the existence of unphysiological foreign phases. These results lead to the requirement for a crystallographic phase purity of the implant materials that are used.

The two main types of calcium phosphate, tricalcium phosphate (TCP) and hydroxylapatite (HA) have different areas of application corresponding to the differences in their resorption: TCP is particularly advantageous as a temporary bone substitute where in the course of time the biomaterial is resorbed concurrently with bone regeneration (filling of cysts in the jaw area, filling in of bone defects caused by disease or operations or degenerative bone defects etc.). In contrast HA is preferably indicated for long-term bone replacement such as e.g. in connection with the coating of joint endoprostheses where one wants to avoid direct contact of the stressed bone store with metal or other inert materials.

The object of the present invention is to provide new compounds which have particularly high cartilage-inducing and/or bone-inducing activities in mammals and especially in primates such as humans but do not have the disadvantages of the previously used materials or only to the smallest possible extent. Such compounds should greatly accelerate the healing process of diseases which affect cartilage and/or bones and which

are in particular associated with a loss of bone substance and/or damage to cartilage and/or bone tissue.

This object is achieved according to the invention by a bioactive implant material for bone replacement with cartilage-forming and/or bone-forming activity composed of two components A and B which comprises a cartilage-inducing and/or bone-inducing protein or protein mixture or DNA coding for such a protein or protein mixture as component A, and a matrix material composed of calcium phosphate which has no intrinsic osteogenic activity as component B, and A is applied to B. Preferred embodiments of the invention are described in the subclaims. In particular a material is provided which is composed of the two components A and B in which A denotes a protein or protein mixture composed of one or several homodimeric or heterodimeric proteins from the TGF- β superfamily with cartilage-inducing and/or bone-inducing activity and B denotes an osteoinductive carrier matrix preferably composed of a biodegradable bone ceramic particularly preferably of α - or β -tricalcium phosphate ceramics. A is associated with B without being covalently bound and can for example be slowly released from B during the bone formation process to the same extent that B is subject to chemical degradation in the bone store. Hence A is subject to a so-called controlled release.

Alternatively A can also denote a DNA coding for the said proteins or protein mixtures. The DNA can optionally be protected from degeneration by methods known to a person skilled in the art. After release into the surrounding tissue, such a DNA can be taken up by the cells that are present there or by cells that migrate into the carrier matrix and be expressed so that

the expressed proteins or protein mixtures act in turn as the active substance.

Hence the DNA is preferably associated with sequences which cause or promote expression. Expression can be promoted especially by specific recombination into the cell genome and namely at a site which leads to the generation of protein under the control of cellular sequences.

On the other hand DNA can also be used on a suitable expression vector.

The term "protein of the TGF- β superfamily with a cartilage-inducing and/or bone-inducing activity" denotes a protein which in its mature part contains the characteristic 7 conserved cysteines. This includes members of the TGF- β , activin, BMP and GDF family and in particular MP52 and fragments thereof with basically the same activity. The corresponding nucleotide and protein sequences are given in the aforementioned citations to the disclosure of which reference is herewith made. These preferably include homodimers of the said proteins and also heterodimers of various family members. Proteins are preferably included which have the same receptor mechanism and/or the same signal transmission as the members of the BMP and/or GDF family, in particular MP52. It also includes a combination of various proteins from the TGF- β superfamily with cartilage-inducing and/or bone-inducing activity. The cartilage-inducing and/or bone-inducing potential can be tested in known experiments such as e.g. *in vivo* by induction of cartilage and/or bones after implantation of the protein with a suitable carrier matrix into rat

musculature; cf. e.g. Sampath, T.K. et al., J. Biol. Chem. 267 (1992) 20352-20362 and/or *in vitro* by induction of alkaline phosphatase activity in ROB-C26 cells; cf. Yamaguchi, A. et al., J. Cell Biol. 113 (1991) 681-687 and/or W-20-17 cells; cf.: Thies, R.S. et al. Endocrinol. 130 (1992) 1318-1324 and/or stimulation of the expression of proteins of the extracellular matrix, cf.: Hock, J.M. et al. Endocrinol. 126 (1990) 421-426 and/or in experiments as described by Chen, P. et al., Exp. Cell Res. 195 (1991) 509-515 and/or Vukicevic, S., et al. Proc.Natl.Acad.Sci. USA 86 (1989) 8793-8797. The protein can be present as a mature protein and also as a precursor protein or a protein in which the propeptide part has been processed in different ways and/or a protein with additional or modified N-terminal and/or C-terminal amino acid sequences which essentially do not influence the biological activity.

On the other hand fusion proteins are also possible which, in addition to the part coding for the mature protein or fragments thereof, additionally still contain functional signal or/and propeptide parts of other proteins in particular of the TGF- β superfamily and especially also of activin, BMP and GDF proteins. The corresponding nucleotide and protein sequences are also found in the above-mentioned citations to the disclosure of which reference is herewith made. It is important that the correct reading frame for the mature protein is retained. Thus for example the exchange of propeptide parts by corresponding parts of other proteins is described in Mol. Endocrinol. 5 (1991), 149-155 and Proc.Natl.Acad.Sci. USA 90 (1993), 2905-2909.

The protein in the compound according to the invention or the protein coded thereby can contain substituted or

inserted amino acids or contain deletions, also provided that the activity is not significantly influenced and can be isolated from various species such as e.g. humans, mouse, rat, cow or pig. Furthermore the protein can be modified by methods known in the prior art such as glycosylations, phosphatizations, sulfations and esterification with fats also provided that this does not result in a significant change in the activity.

In a preferred embodiment of the present invention A is a protein from the GDF or BMP family or a fragment thereof.

In a particularly preferred embodiment of the present invention the component A is characterized by a protein which

- (a) contains the mature part and optionally additional functional parts of the protein sequence shown in SEQ ID NO. 1,
- (b) contains parts of the mature part of (a) which have essentially the same activity, in particular mature proteins with a modified N-terminus,
- (c) contains parts corresponding to (a) or (b) which differ from SEQ ID NO:1 due to the origin of the protein from other vertebrates but have essentially the same activity,
- (d) in addition to containing parts of the mature protein according to (a), (b) or (c), also contains parts of another protein from the TGF- β superfamily in the form of a fusion protein,
- (e) in addition to containing monomeric mature proteins according to (a) to (d), also contains a monomer of another protein from the TGF- β superfamily with formation of heterodimers,
- (f) in addition to containing dimeric mature proteins

according to (a) to (e), also contains at least one dimer of another protein from the TGF- β superfamily.

This embodiment in particular comprises the mature protein MP52 or functional parts or fragments thereof in which the active form is preferably present as a dimer. Functional regions or sections or fragments are particularly preferred which contain at least the region of the seven conserved cysteines.

A "biocompatible" and "bioactive" carrier matrix denotes in the osteological sense a calcium phosphate ceramic which, on the one hand, can be integrated into bones without damaging tissue reactions such as connective tissue encapsulations, inflammations and tissue degenerations and, on the other hand, stimulates a direct growth of bones onto or into the surface structure of the implant. However, "bioactivity" of a carrier matrix is not present until a histologically and clinically detectable stimulation of bone growth occurs. There is clinical experience with the highly porous bioactive carrier matrix (such as e.g. Cerasorb®) according to the invention which is based on tricalcium phosphate, in particular on β -TCP and also α -TCP. The phase-pure and open microporous β -TCP has an outstanding position with regard to bioactivity or osteoinductivity and alone produces an ion environment as a result of the predictable chemical dissolution in the bone store which contributes to the stimulation of osteoblast activity and in situ serves as a substrate for osteoblast activity. If the chemical dissolution or resorption of the carrier matrix occurs simultaneously with the primary phase of bone formation (woven bone phase) there is an excellent chance of regaining the strength and structure of the surrounding bone store. A prerequisite

for this is the absence of unstoichiometric secondary phases which often react unphysiologically. This can be demonstrated for phase-pure β -TCP and it therefore already alone has an osteoinductive action. Crystallographically phase-pure α - or β -tricalcium phosphate ceramics with an interconnecting microporosity in the range of 20-60 % of their volume are particularly preferred. In a particularly preferred embodiment the primary particle size of the crystallographically phase-pure α - or β -tricalcium phosphate ceramics is in the range of 10 - 40 μm . In a further preferred embodiment of the invention this implant material is present in the form of an injectable suspension. This for example enables the material to be applied with a minimum of invasiveness. Hence a suspension of this matrix in suitable liquids for medical applications such as water, serum, plasma and blood does not cause any infiltration of giant cells or connective tissue into the implant.

Hence an important subject matter of the invention is an implant material composed of two components A and B in which the osteopoetic effect of component A is synergistically amplified by an osteoinductive effect of component B. Hence the compound is based on an advantageous combination of mechanisms of action of two components i.e. a cartilage-inducing and/or bone-inducing protein or protein mixture and an osteoinductive carrier matrix. Such an implant material according to the invention avoids counter-productive effects with regard to the osteopoetic effect of the proteins A which some biocompatible but not bioactive implant materials exhibit. Thus carrier materials such as HA are often unsuitable for an application in protein-stimulating oestrosynthesis due to their slow biodegradability. Rapidly biodegradable carrier ceramics such as phosphate

glasses and metastable phases or phase mixtures of CaP and also of chemically modified matrices which are for example obtained from corals have already alone a counter-productive effect on protein-stimulating osteosynthesis due to the activation of macrophages or/and osteoclasts. Furthermore it has turned out that coating the matrix surface of suitable carrier materials with physiologically inert protein fillers such as collagen has an inhibitory effect on resorption and thus on bioactivity. Surprisingly mixtures of carrier materials based on microporous phase-pure TCP, preferably β -TCP, with homogenates of red bone marrow or blood have been shown to promote osteosynthesis despite the considerable coverage of the matrix surface with proteins. Hence the implant materials according to the invention represent an optimization of these results. The minimal matrix coverage with the protein or DNA component A ensures the maintenance of the bioactive, i.e. intrinsic, osteoinductive properties of the carrier matrix B from which component A is inevitably released through its interconnecting micropore structure and is thus biologically active to an extent corresponding to the chemical degradation of the matrix at the site of implantation. If it were not combined with a suitable matrix, the osteopoetic protein A alone would rapidly lose its biological activity at the site of implantation due to metabolism, transport by body fluids or phagocytosis. The phase purity of the carrier matrix with a defined micropore structure ensures a predictable resorption and thus also a controlled release of the protein component A or of a DNA coding therefor. Such an interaction between matrix B and protein A undoubtedly represents a synergistic amplification of the effects of the two components A and B.

A further subject matter of the present invention is a process for the production of the implant materials according to the invention in which a solution of the protein A or DNA in a physiologically acceptable, water-miscible solvent or in appropriate solvent mixtures is applied to the microporous structure of the biocompatible matrix B in such a way that the component A is distributed homogeneously in and/or on the microporous structure of the matrix.

Information on the production of proteins of the TGF- β superfamily, their expression in suitable host cells and purification may be found in numerous already cited publications and patent documents. In particular reference is made to WO 95/04819 and DE 19525416.3 as well as to Hötten et al. (Growth Factors 13 (1996) 65-74) for the preparation of MP52/GDF-5 or active fragments thereof.

If the proteins are produced in bacteria where the proteins are present in the form of inclusion bodies as is the case for MP52, they are renatured by known methods in order to obtain the protein, for example MP52, in an active form. MP52-like proteins expressed in *E. coli* can be refolded into an active protein cf.: Krieglstein, K. et al., *J. Neuroscience Res.* 42 (1995) 724-732. Exact procedures are also described in the Japanese Patent Application Hei7('95)-93664 as well as in DE 19525416.3. Other investigations by us as well as by Ruppert, R. et al. (*Eur. J. Biochem.* 237, 295-302 (1996)) have shown that for example BMP-2 can also be expressed in *E. coli* and refolded to form the dimer.

The DNA is prepared by methods known to a person skilled

in the art as described for example in Current Protocols in Molecular Biology (Ausubel et al., Greene Publishing Associates and Wiley-Interscience, Wiley & Sons, 1987-1996) or in Molecular Cloning (Sambrook et al., second edition, Cold Spring Harbor Laboratory Press 1989).

The following procedure according to DE 38 10 803 C2 can be used to prepare the carrier matrix B: homogeneous stoichiometric mixtures of CaCO_3 and CaHPO_4 are subjected in various steps to sintering temperatures up to 1350°C in compacted moulded bodies according to the constitution diagram (phase diagram) of the system CaO and P_2O_5 (Trömel, Stahl und Eisen 63 (1943) 21; Welch, J.Chem.Soc. (1961) 4442) in which water and CO_2 are removed from the sintering system. Between the sintering processes the intermediate stages of the sintering synthesis are comminuted, micronized, recompacted for the production of moulded articles or pelletized for granulate production. The sintering processes are carried out with respect to time and temperature such that coexisting neighbouring phases of TCP according to the phase diagram are avoided i.e. in particular tetra calcium phosphate on the one hand and dicalcium phosphate on the other hand. Metastable phases of the thermodynamically stable $\beta\text{-Ca}_3(\text{PO}_4)_2$ or $\beta\text{-TCP}$ can either be specifically avoided by regulating the sintering process according to the intended application or can be intentionally made to coexist or can even be prepared alone as the dominant product.

A homogeneous incorporation and distribution of the component A in the pore structure of the carrier matrix B requires several types of process which enable such a distribution without the component itself being changed by the processes.

Thus it is obvious that a combination of A and B cannot be used simultaneously in the ceramic sintering process due to the high process temperatures.

In contrast it is possible to penetrate the microporous ceramic structure of the moulded parts and granulate particles with solutions of the proteins A or the DNA coding therefor according to the invention in suitable solvents in which the capillary forces of the open ceramic structure become effective. When selecting solvents, of course only those come into consideration which do not alter the characteristics of the components A and B of the biomaterial. Thus for example acidic solvents are unsuitable which although being excellent solvents for osteopoietic proteins, attack and chemically modify the calcium phosphates. On the other hand water is neutral towards ceramics but is often only able to incompletely dissolve the protein components A. A penetration by means of suspensions would not allow a homogeneous distribution in the carrier matrix due to the microporous structure.

A process for penetrating the carrier matrix by means of the solvent phase which could obviously be driven out by evaporation, also does not lead to a completely homogeneous distribution of A in B since when the solvent evaporates on the surface of the porous ceramics there is a mass transport of the dissolved phase from the inside to the outside resulting in a concentration on the surface.

A solution for this complex problem of homogeneously dosing the carrier matrix with component A can be accomplished according to the invention by the following

types of process:

- Removing the solvent after cooling a gently heated solution saturated with the proteins A. As a result the limit of solubility of the proteins in the solvent is exceeded and the proteins are deposited in the carrier structure. This reduces the amount of protein in the remaining solution and correspondingly reduces the described concentration effect. There is a natural limit to this method due to the small temperature margin, but it is especially appropriate when a quantity gradient of the protein in the ceramic structure is desirable with regard to a certain starter effect on osteopoesis.
- Removing a protein-containing or DNA-containing liquid mixture composed of organic solvent and/or water by sublimation according to critical point drying. The direct transition of the solidified solvent mixture into the gaseous state prevents transport of the protein or the DNA via the liquid phase and results in a uniform distribution of the precipitated protein or the DNA in the ceramic structure.
- Homogeneous precipitation of protein in the ceramic carrier structure from a protein-containing organic solution by adding for example water which leads to a rapid precipitation of the protein and thus to an in situ deposition in the ceramic structure. This method can be used in various ways and works with substance pairs in which the protein is soluble in the organic solvent, the pure solvent is miscible

with water but not the protein-containing solution. Acetonitrile/water, propanediol-1,2/water or propanol/water can, among others, for example be used for this.

- Homogeneous precipitation of DNA in a ceramic carrier structure from a DNA-containing salt solution (for example 0.1 M NaCl or 0.25 M NaAc) by adding an alcoholic solution such as absolute ethanol which leads to a rapid precipitation of the DNA in the ceramic structure. The doped carrier matrix can if necessary be washed with 70 % ethanol.

The efficacy of the implant materials according to the invention can be tested in conventional test systems such as e.g. the already mentioned rat, dog, rabbit or also primate animal models.

Further subject matters of the present invention are therefore a pharmaceutical composition containing an implant material optionally together with pharmaceutically as well as physiologically acceptable auxiliary substances, diluents and/or fillers and the use of the compounds according to the invention at a pharmaceutically effective concentration optionally together with pharmaceutically as well as physiologically acceptable auxiliary substances, diluents and/or fillers for the local treatment of cartilage and/or bone diseases and/or of damage to cartilage and/or bone tissue caused by injury, operation, degeneration or strain in vertebrates and in particular in mammals such as humans.

The compounds according to the invention can be used to specifically treat diseases which are associated with bone loss caused for example by age, metabolic diseases or inflammatory processes.

Damage to cartilage or bone tissue can occur after injury such as sport injuries, accidents, straining the apparatus of locomotion or can occur as a result of operations for example due to drill holes in the bones after removing screws for artificial fastening apparatuses or after resections of tumour tissue. The specific local treatment of bone fractures is particularly preferred. It is also possible to elongate limbs. Applications in the dental or jaw region are of particular interest such as the treatment of periodontosis, sinus lift or cyst filling in the jaw area. There are also applications in cosmetic surgery in particular plastic surgery in the facial region. The compounds according to the invention also enable two movable bone parts to be immobilized such as e.g. the connection of two vertebrae by means of a newly formed bone bridge which can for example be advantageous for intervertebral disk problems. The said methods of treatment also include veterinary medicine.

The dose is in the range of 10 μ g to 100 mg depending on the type of protein component and on the type of application, the disease and the state of the patient. The amount of carrier matrix depends on the size of the bone or cartilage defect which is to be treated.

If large pressed carrier matrices are used they have to be mechanically fixed by for example steel rods and screws.

The synergistic effect which is the basis of this invention achieved by combining mechanisms of action of two components in a compound i.e. cartilage-inducing and/or bone-inducing protein and osteoinductive carrier matrix enables very good results to be achieved in treatments.

An advantage of the implant materials according to the invention is that it is possible to substantially improve and accelerate healing processes that require cartilage-inducing and/or bone-inducing reactions. This advantageously results in a considerable reduction of the period of suffering for the patients, shorter periods out of work and a reduction of the costs for hospital stays. A further economic aspect is the effective treatment of the wide-spread disease periodontosis which is accompanied by a premature loss of teeth. Thus economically tooth preservation made possible by periodontosis treatment contrasts with expensive premature dentures.

A short description of the figures follows:

SEQ ID NO.1 shows the complete amino acid sequence of the precursor protein of the human TGF- β protein MP52. The start of the mature protein is preferably in the region of amino acids 361-400, particularly preferably at amino acid 381 or 382. The mature part of the protein contains the seven conserved cysteines at positions 400, 429, 433, 465, 466, 498 and 500.

Figure 1 and 2 show the osteoinductive effect of the carrier matrix according to the invention compared to a biocompatible but not bioactive matrix.

SEQUENCE PROTOCOL

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Biopharm Gesellschaft zur biotechnologischen
Entwicklung von Pharmaka mbH
- (B) ROAD: Czernyring 22
- (C) CITY: Heidelberg
- (E) COUNTRY: Germany
- (F) POSTAL CODE: 69115

- (A) NAME: GerontoCare GmbH Biomaterials & Medical
Devices
- (B) ROAD: Rossberggring 107
- (C) CITY: Reinheim/odw.
- (E) COUNTRY: Germany
- (F) POSTAL CODE: 64354

(ii) TITLE OF INVENTION:

Compounds with improved cartilage-inducing
and/or bone-inducing activity

(iii) NUMBER OF SEQUENCES: 1

(iv) COMPUTER-READABLE FORM:

- (A) DATA CARRIER: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, version #1.30
(EPO)

(vi) DATA OF THE ORIGINAL APPLICATION:

- (A) APPLICATION NO: DE 19647853.7
- (B) DATE OF APPLICATION: 19-Nov-1996

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 501 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) TYPE OF MOLECULE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp
1 5 10 15

Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly
20 25 30

Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys
35 40 45

Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser
50 55 60

Tyr Gly Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr
65 70 75 80

Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys
85 90 95

Leu Pro Pro Arg Pro Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro
100 105 110

Gln Thr Arg Gln Ala Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu
115 120 125

Pro Gly Gly Lys Ala Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe
130 135 140

Leu Leu Lys Lys Ala Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu
145 150 155 160

Pro Phe Arg Pro Pro Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu
165 170 175

Tyr Arg Thr Leu Ser Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val
180 185 190

Lys Leu Glu Ala Gly Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys
195 200 205

Gly Gln Asp Asp Arg Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe
210 215 220

Asp Ile Ser Ala Leu Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg
225 230 235 240

Ile Leu Arg Lys Lys Pro Ser Asp Thr Ala Lys Pro Ala Ala Pro Gly
245 250 255

Gly Gly Arg Ala Ala Gln Leu Lys Leu Ser Ser Cys Pro Ser Gly Arg
260 265 270

Gln Pro Ala Ser Leu Leu Asp Val Arg Ser Val Pro Gly Leu Asp Gly
275 280 285

Ser Gly Trp Glu Val Phe Asp Ile Trp Lys Leu Phe Arg Asn Phe Lys
290 295 300

Asn Ser Ala Gln Leu Cys Leu Glu Leu Glu Ala Trp Glu Arg Gly Arg
305 310 315 320

Ala Val Asp Leu Arg Gly Leu Gly Phe Asp Arg Ala Ala Arg Gln Val
325 330 335

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp
340 345 350

Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr
355 360 365

Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu
370 375 380

Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys
385 390 395 400

Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp
405 410 415

Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu
420 425 430

Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val
435 440 445

Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr
450 455 460

Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp
465 470 475 480

Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu
485 490 495

Ser Cys Gly Cys Arg
500

Figures 1 and 2 show the osteoinductive activity of the carrier matrix according to the invention as compared with the biocompatible, albeit not bioactive matrix. Figure 1 schematically shows the bone formation in the pores of a bioinert matrix e.g. Al_2O_3 (1 in Fig. 1). Figure 3 in comparison shows the osteoinductive effect of the calcium phosphate matrix according to the invention (1 in Fig. 2) in an otherwise identical implant situation:

In both cases cylindrical implants (1) (outer diameter: 6 mm) having an open macroporosity throughout (pore diameter ca. 0.5 to 0.7 mm \varnothing) were implanted into compact bones (tibia of a dog). The compact storage bone (2) having a clearly visible lamellar structure forms new bone around the implant after a short implantation period which attempts to bridge the intermediate space between the drilled hole in the bone and the outer edge of the implant (3). In addition new bone also forms in the pores of the implant (4a in Fig. 1 and 4b in Fig. 2).

The significant difference between the two implant materials is that the bone in the osteoinductive implant material (4b in Fig. 2) is formed immediately and spontaneously on the inner surfaces of the pores and the carrier matrix is used as a site of nucleation and from there fills the entire implant region. In contrast the bone grows very slowly in the non-bioactive material (Fig. 1) through the middle of the pores and permanently avoids direct contact with the implant material. These differences result in a very intensive and rapid composite formation in the case of the osteoinductive material (Fig. 2) and in a delayed incomplete formation in the case of the bioinert material which is accompanied by osteoclast activity (Fig. 1).

Claims

1. Bioactive implant material for bone replacement having cartilage-forming and/or bone-forming activity composed of two components A and B, **wherein**
A is an osteoinductive protein or protein mixture or a DNA coding for one or several such proteins applied on B and B is a matrix material composed of calcium phosphate which has an intrinsic osteogenic activity.
2. Implant material as claimed in claim 1, wherein component A comprises one or several homodimeric or heterodimeric proteins of the TGF- β superfamily with a cartilage-inducing and/or bone-inducing activity preferably of the GDF or BMP family or fragments thereof or DNA sequences coding therefor.
3. Implant material as claimed in claim 1 or 2, wherein component A
 - (a) contains the mature part and optionally additional functional parts of the protein sequence shown in SEQ ID NO. 1,
 - (b) contains parts of the mature part of (a) which have essentially the same activity, in particular mature proteins with a modified N-terminus,
 - (c) contains parts corresponding to (a) or (b) which differ from SEQ ID NO:1 due to the origin of the protein from other vertebrates but have essentially the same activity,
 - (d) in addition to containing parts of the mature



- protein according to (a), (b) or (c), also contains parts of another protein from the TGF- β superfamily in the form of a fusion protein,
- (e) in addition to containing monomeric mature proteins according to (a) to (d), also contains a monomer of another protein from the TGF- β superfamily with formation of heterodimers,
 - (f) in addition to containing dimeric mature proteins according to (a) to (e), also contains at least one dimer of another protein from the TGF- β superfamily.
4. Implant material as claimed in one of the claims 1 to 3, wherein B denotes a biodegradable or/and bioactive carrier matrix composed of tricalcium phosphate ceramics which is composed of crystallographically phase-pure α - or β -tricalcium phosphate ceramics with an interconnecting microporosity in the range of 20-60 % of its volume and alone already has bone-inducing properties.
5. Implant material as claimed in claim 4, wherein B denotes a biodegradable or/and bioactive carrier matrix composed of crystallographically phase-pure α - or β -tricalcium phosphate ceramics with a primary particle size in the range of 10-40 μm and in a suitable suspension for a medical application in suitable liquids such as water, serum, plasma and blood, causes no giant cell or connective tissue infiltration into the implant.

6. Implant material as claimed in claims 4 or 5,
wherein
it is present in the form of an injectable suspension.
7. Implant material as claimed in claims 4, 5 or 6,
wherein B denotes a biodegradable and bioactive
carrier matrix composed of crystallographically
phase-pure α - or β -tricalcium phosphate ceramics
which releases A in a controlled retarded manner
(controlled release) to the extent that B is
subjected to chemical degradation in the bone
store.
8. Process for the production of a bioactive implant
material as claimed in one of the claims 1 to 7 in
which the protein or the DNA sequence A is applied
in the microporous structure of the biocompatible
matrix B as a solution in a physiologically
acceptable, water-miscible solvent or in
appropriate solvent mixtures in such a way that a
homogeneous distribution of A in and/or on the
microporous structure of the matrix is achieved.
9. Process for the production of a compound as claimed
in claim 8, wherein the solvent or solvent mixture
is removed by sublimation preferably by freeze
drying.
10. Process for the production of a compound as claimed
in claim 8, wherein the protein or the DNA sequence
A is concentrated by in situ precipitation in the
matrix B from the solvent by admixing a
precipitating solvent which is preferably water or
ethanol.

11. Pharmaceutical composition containing an implant material as claimed in one of the claims 1 to 7 optionally together with pharmaceutically as well as physiologically acceptable auxiliary substances, diluents and/or fillers.
12. Use of a bioactive implant material as claimed in one of the claims 1 to 7 or of a pharmaceutical composition as claimed in claim 11 for the local treatment of diseases which affect cartilage and/or bones or/and of damage to cartilage and/or bone tissue caused by injury, operation, degeneration or strain.
13. Use of a bioactive implant material as claimed in one of the claims 1 to 7 or of a pharmaceutical composition as claimed in claim 11 for the treatment of bone defects such as periodontosis, sinus lift, cyst filling in the jaw region, bone fractures, bone replacement as well as for applications in cosmetic and plastic surgery and for immobilizing movable bone parts.

Abstract

The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or cartilage-inducing protein or protein mixture and preferably one or several proteins from the TGF- β superfamily, preferably MP52 or a DNA sequence coding therefor and B is a carrier matrix composed of calcium phosphate ceramics with an interconnecting microporosity which already alone has bone-inducing properties. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones as well as to treat damage to cartilage and/or bone tissue.



Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
(Insert Title) Compounds with improved cartilage-inducing and/or
bone-inducing activity

the specification of which

- (Check one of blocks 1, 2 or 3. See note A on back of this page)
1. ☐ is attached hereto.
2. ☒ was filed on 19 November 1997 as
International PCT Application Serial No. PCT/EP97/06463
and was amended on _____
(if applicable)
3. ☐ was filed on _____ as
U.S. Application Serial No. _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application for which priority is claimed:

(List prior foreign applications. See note B on back of this page)	<u>196 47 853.7</u> (Number)	<u>Germany</u> (Country)	<u>19/Nov/1996</u> (Day/Month/Year Filed)	Priority Claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

(See Note C on back of this page)

☐ See attached list for additional prior foreign applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(List prior U.S. Applications or PCT International applications designating the U.S.)	(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
	_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

And I hereby appoint as principal attorneys David T. Nikaïdo, Reg. No. 22,663; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Robert B. Murray, Reg. No. 22,980; Martin S. Postman, Reg. No. 18,570; E. Marcie Emas, Reg. No. 32,131; Michael G. Gilman, Reg. No. 19,114; Douglas H. Goldhush, Reg. No. 33,125; Kevin C. Brown, Reg. No. 32,402; Monica Chin Kitts, Reg. No. 36,105; Sharon N. Klesner, Reg. No. 36,335, and John R. Fuisz, Reg. No. 37,327.

Please direct all communications to the following address: NIKAIDO, MARMELESTEIN, MURRAY & ORAM
Metropolitan Square
655 Fifteenth Street, N.W., Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000 Fax: (202) 638-4810

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(See Note D on back of this page)

Full name of sole or first inventor Michael PAULISTA

Inventor's signature Michael Paulista 5.7.99

Residence D-69181 Leimen, Federal Rep. of Germany Date

Citizenship German DEX

Post Office Address Wingertstraße 10, D-69181 Leimen, Germany

2-00
Full name of second joint inventor, if any Jens POHL
Inventor's signature *Jens POHL* Date *March 5, 1999*
Residence D-76707 Hambrücken, Federal Republic of Germany
Citizenship German DEX
Post Office Address Bastwaldstraße 25, 76707 Hambrücken, Germany

3-00
Full name of third joint inventor, if any Joachim PARST
Inventor's signature *Joachim PARST* Date *April 6, 1999*
Residence D-64354 Reinheim, Federal Republic of Germany
Citizenship German DEX
Post Office Address Rossberggring 107, D-64354 Reinheim, Germany

4-00
Full name of fourth joint inventor, if any Helmut HEIDE
Inventor's signature *Helmut HEIDE* Date *April 6, 1999*
Residence D-65779 Kelkheim, Federal Republic of Germany
Citizenship German DEX
Post Office Address Am Hohenstein 14, D-65779 Kelkheim, Germany

Full name of fifth joint inventor, if any _____
Inventor's signature _____
Residence _____ Date _____
Citizenship _____
Post Office Address _____

Full name of sixth joint inventor, if any _____
Inventor's signature _____
Residence _____ Date _____
Citizenship _____
Post Office Address _____

Full name of seventh joint inventor, if any _____
Inventor's signature _____
Residence _____ Date _____
Citizenship _____
Post Office Address _____

Full name of eighth joint inventor, if any _____
Inventor's signature _____
Residence _____ Date _____
Citizenship _____
Post Office Address _____